論文

査読有り 国際誌
2021年4月12日

Severe infection risk in patients treated with biologics for rheumatoid arthritis: a systematic review protocol.

JBI evidence synthesis
  • Kiyoko Makimoto
  • ,
  • Rie Konno
  • ,
  • Hatsumi Kanzaki
  • ,
  • Atsushi Kinoshita

19
8
開始ページ
1992
終了ページ
1998
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.11124/JBIES-20-00372

OBJECTIVE: To estimate the population-based incidence and determine the types of severe infection experienced by patients with rheumatoid arthritis who are taking biological agents. INTRODUCTION: Since the late 1990 s, a variety of biological and synthetic drugs have been developed to treat rheumatoid arthritis. In recent years, the incidence of severe infection in patients with rheumatoid arthritis in Western nations has been reported by observational studies; however, no systematic review has been conducted on this topic. INCLUSION CRITERIA: The following criteria will be considered for inclusion: i) observational studies on patients with rheumatoid arthritis who are on biological treatment; ii) studies reporting the number of severe infections requiring hospitalization for treatment; and iii) studies with person-years of observational data. METHODS: MEDLINE, CINAHL, Embase, and Web of Science will be searched to identify published studies. The reference list of all studies that are selected for critical appraisal will be screened for additional studies. The search for unpublished studies will include MedNar and OpenGrey. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD42020175137.

リンク情報
DOI
https://doi.org/10.11124/JBIES-20-00372
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33851946
ID情報
  • DOI : 10.11124/JBIES-20-00372
  • PubMed ID : 33851946

エクスポート
BibTeX RIS